LABA/LAMA vs LABA/ICS: The path to the FLAME trial

Professor David Price discusses the hypothesis for the superior efficacy of LABA/LAMA versus LABA/ICS in COPD patients with a history of ≥1 exacerbation, and how this hypothesis was confirmed by the FLAME trial.